Skip to content
  1. Home
  2. >Test Catalog
  3. >Pharmacogenomics
  4. >Pgx Mental Health Panel
Back to catalog

Pharmacogenomics (PGx) Mental Health Panel

Turnaround

6-9 days

Turnaround Requery

≤ 5 minutes

Panel Description

Many medications for mental health disorders are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring, can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.

This panel includes 36 medications and 9 genes associated with Mental Health. Results from this test may help in predicting treatment efficacy and risk of side effects for drugs used to treat various mental health disorders.

View the complete description of this panel
Sample report

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

(844) 211 2070clinicalsupport@helix.com

Genes Tested

ABCB1
COMT
CYP2C9
CYP2C19
CYP2D6
CYP3A4
HLA-B
MTHFR
OPRM1

Showing 9 of 9 genes in this panel

Other Tests to Consider

Test

Malignant Hyperthermia Susceptibility Panel

3

genes

Test

Pharmacogenomics (PGx) APOE Test

1

gene

Test

Pharmacogenomics (PGx) Fluoropyrimidines DPYD Test

1

gene

Test

Pharmacogenomics (PGx) Level A Panel

16

genes

Important Panel Information

Turnaround time: Typically 7-10 days (standard), Typically < 5 minutes (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

This test utilizes next-generation sequencing to determine results for ABCB1, COMT, CYP2C9, CYP2C19, CYP3A4, CYP2D6, HLA-B, MTHFR, OPRM1 . These results are used to determine drug considerations for the following drugs: Amitriptyline, Amphetamine, Aripiprazole, Atomoxetine, Brexpiprazole, Brivaracetam, Carbamazepine, Citalopram, Clobazam, Clomipramine, Clozapine, Desipramine, Deutetrabenazine, Doxepin, Escitalopram, Flibanserin, Fluvoxamine, Haloperidol, Iloperidone, Imipramine, Lamotrigine, Lofexidine, Nortriptyline, Oxcarbazepine, Paroxetine, Pimozide, Quetiapine, Risperidone, Sertraline, Thioridazine, Trimipramine, Valbenazine, Venlafaxine, and Vortioxetine.

Additionally, due to lack of sufficient scientific evidence, genetic outcomes are provided without drug considerations for the following drugs: Alprazolam, Amoxapine, Aripiprazole, Brexpiprazole, Buprenorphine, Bupropion, Buspirone, Cariprazine, Clonazepam, Clozapine, Desvenlafaxine, Diazepam, Duloxetine, Eszopiclone, Flibanserin, Fluoxetine, Fluoxetine, Iloperidone, Levomilnacipran, Lithium, Lurasidone, Maprotiline, Methylphenidate, Mirtazapine, Mirtazapine, Naloxone, Olanzapine, Paliperidone, Perphenazine, Pimozide, Protriptyline, Trazodone, Triazolam, Vilazodone, Viloxazine, Ziprasidone, and Zolpidem.

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.